![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2021
Anzahl der Publikationen: 2
2021
O'Shaughnessy, Joyce A.; Johnston, Stephen; Harbeck, Nadia; Toi, Masakazu; Im, Young-Hyuck; Reinisch, Mattea; Shao, Zhimin; Lehtinen, Pirkko Liisa Kellokumpu; Huang, Chiun-Sheng; Tryakin, Alexey; Goetz, Matthew; Rugo, Hope S.; Senkus, Elzbieta; Testa, Laura; Andersson, Michael; Tamura, Kenji; Steger, Guenther G.; Del Mastro, Lucia; Cox, Joanne; Forrester, Tammy; Sherwood, Sarah; Li, Xuelin; Wei, Ran; Martin, Miguel und Rastogi, Priya
(2021):
Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer.
In: Clinical Advances in Hematology & Oncology, Bd. 19, Nr. 2: S. 15-16
Winer, Eric P.; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime und Cortes, Javier
(2021):
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
In: Lancet Oncology, Bd. 22, Nr. 4: S. 499-511